ProCE Banner Activity

Tumor Treating Fields + Immune Checkpoint Inhibition in Metastatic NSCLC After Platinum Failure: Phase III LUNAR Subgroup Analysis by PD-L1 Expression

Conference Coverage

This exploratory post hoc analysis of the phase III LUNAR trial suggests that the survival benefit with TTFields + ICI therapy after progression on/after platinum-based chemotherapy is more pronounced in patients with PD-L1–positive (TPS ≥1%) metastatic NSCLC vs those with PD-L1–negative disease.

Released: September 14, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences Inc., and Regeneron Pharmaceuticals, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc